Conditions: 0.25 mg · four weeks · constipation.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
Why does this happen, and what would falsify the usual explanation?
four weeks at 0.25 mg is 28 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 0.25 mg back by 28 days. Whether that reduces constipation depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 0.25 mg is 0.25 mg on day 1 and on day 28. A symptom driven by the rate of change has 28 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot constipation against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
This is the single most consequential controllable variable in the whole experience, and people routinely rush it.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|---|---|---|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Hold rather than escalate while symptoms are active. Always.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
To be exact about it, the dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Four half-lives between steps, minimum. Work it out for your agent.
Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Put another way, titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Nothing here is medical advice, and research-use compounds are not approved for human use.
The top of the schedule is not the target. The working dose is.
Specifically, the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
Slower costs time and nothing else. The ceiling is the same.
edited 5 Apr 2026 by a_lindgren — added the citation requested in comments
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Stepping back is a normal adjustment, not a failure.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.